BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process

Reuters

13 Mar

BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process

March 13 (Reuters) - Trinity Biotech PLC TRIB.O:

TRINITY BIOTECH FURTHER STRENGTHENS FOCUS ON CONTINUOUS GLUCOSE MONITORING – APPOINTS BARCLAYS TO ADVISE ON ONGOING STRATEGIC REALIGNMENT PROCESS
TRINITY BIOTECH PLC: DETERMINED THAT CGM TECHNOLOGY AND RELATED DATA DRIVEN INSIGHTS WILL BE CO'S PRIMARY STRATEGIC FOCUS MOVING FORWARD

Source text: ID:nGNX2R8H4l

Further company coverage: TRIB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2519838194"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519838194\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2519838194?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-13 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519838194","market":"nz","top_or_hot":-1,"title":"BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process</title></head><body><p><span>March 13 (Reuters)</span><span> - </span>Trinity Biotech <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>TRIB.O</span>:</p><ul><li><p>TRINITY BIOTECH FURTHER STRENGTHENS FOCUS ON CONTINUOUS GLUCOSE MONITORING – APPOINTS BARCLAYS TO ADVISE ON ONGOING STRATEGIC REALIGNMENT PROCESS</p></li><li><p>TRINITY BIOTECH PLC: DETERMINED THAT CGM TECHNOLOGY AND RELATED DATA DRIVEN INSIGHTS WILL BE CO'S PRIMARY STRATEGIC FOCUS MOVING FORWARD</p></li></ul><p>Source text: <span>ID:nGNX2R8H4l</span></p><p>Further company coverage: <span>TRIB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-13 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment process</title></head><body><p><span>March 13 (Reuters)</span><span> - </span>Trinity Biotech <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>TRIB.O</span>:</p><ul><li><p>TRINITY BIOTECH FURTHER STRENGTHENS FOCUS ON CONTINUOUS GLUCOSE MONITORING – APPOINTS BARCLAYS TO ADVISE ON ONGOING STRATEGIC REALIGNMENT PROCESS</p></li><li><p>TRINITY BIOTECH PLC: DETERMINED THAT CGM TECHNOLOGY AND RELATED DATA DRIVEN INSIGHTS WILL BE CO'S PRIMARY STRATEGIC FOCUS MOVING FORWARD</p></li></ul><p>Source text: <span>ID:nGNX2R8H4l</span></p><p>Further company coverage: <span>TRIB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW04Z:1","article_id":"2519838194","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519838194","pubTimestamp":1741865654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment processMarch 13 (Reuters) - Trinity Biotech PLC TRIB.O:TRINITY BIOTECH FURTHER STRENGTHENS FOCUS ON CONTINUOUS GLUCOS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","TRIB":"Trinity Biotech plc"},"translate_title":"简介-Trinity Biotech任命巴克莱银行为正在进行的战略调整过程提供建议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRIB":0.9},"content_text":"BRIEF-Trinity Biotech appoints Barclays to advise on ongoing strategic realignment processMarch 13 (Reuters) - Trinity Biotech PLC TRIB.O:TRINITY BIOTECH FURTHER STRENGTHENS FOCUS ON CONTINUOUS GLUCOSE MONITORING – APPOINTS BARCLAYS TO ADVISE ON ONGOING STRATEGIC REALIGNMENT PROCESSTRINITY BIOTECH PLC: DETERMINED THAT CGM TECHNOLOGY AND RELATED DATA DRIVEN INSIGHTS WILL BE CO'S PRIMARY STRATEGIC FOCUS MOVING FORWARDSource text: ID:nGNX2R8H4lFurther company coverage: TRIB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1}}}